BTLA Antikörper (PE)
Kurzübersicht für BTLA Antikörper (PE) (ABIN7505892)
Target
Alle BTLA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-Hu CD272 PE
-
Produktmerkmale
- The mouse monoclonal antibody MIH26 recognizes an extracellular epitope of CD272, a transmembrane glycoprotein serving as a negative regulator of the activation in various leukocyte types.
-
Aufreinigung
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
-
Immunogen
- cells transfected with human CD272
-
Isotyp
- IgG2a, kappa
-
-
-
-
Applikationshinweise
- Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Do not freeze,Protect from prolonged exposure to light
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
- BTLA (B and T Lymphocyte Associated (BTLA))
-
Andere Bezeichnung
- CD272
-
Hintergrund
- B and T lymphocyte associated,CD272, a type I transmembrane glycoprotein, contains in its intracellular domain two ITIM sequences, which are upon CD272 triggering phosphorylated and recruit SHP phosphatases to attenuate cell activation. CD272 is expressed on B and T lymphocytes, NK cells, dendritic cells, and macrophages, and its ligand is CD270. Defects in CD272-CD270 inhibitory mechanism lead to autoimmune diseases. Overexpression of CD272 is a marker of tolerant T cells.,BTLA1
-
Gen-ID
- 151888
-
UniProt
- Q7Z6A9
-
Pathways
- Cancer Immune Checkpoints
Target
-